Pfizer Shares New Phase 1b Results of Gene Therapy in Ambulatory Boys With Duchenne
PROGRESS! Pfizer announced updated Phase 1b clinical data on PF-06939926, their investigational gene therapy being developed to treat Duchenne. The preliminary data from 9 ambulatory boys with Duchenne, aged 6 to 12 indicate that the…Learn More